Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth H Williams

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLCGareth H Williams, Andrew G Nicholson, David R J Snead, et al.
Journal of the National Cancer Institute|July 18, 2002
Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sedimentsKai Stoeber, Robert Swinn, A Toby Prevost, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2019
Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Chemical Biology & Drug Design|October 11, 2011
Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNAMatt Gooding, Slavica Tudzarova, Roberta J Worthington, et al.
Plos One|July 14, 2012
Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22John D Kelly, Tim J Dudderidge, Alex Wollenschlaeger, et al.
The Oncologist|August 23, 2024
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational studyFrancesco Schettini, Marianna Sirico, Marco Loddo, et al.
Frontiers in Oncology|July 15, 2021
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Silvia Paola Corona, Fabiola Giudici, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLCGareth H Williams, Andrew G Nicholson, David R J Snead, et al.
Journal of the National Cancer Institute|July 18, 2002
Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sedimentsKai Stoeber, Robert Swinn, A Toby Prevost, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2019
Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesNicola L Lawson, Carly I Dix, Paul W Scorer, et al.
Chemical Biology & Drug Design|October 11, 2011
Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNAMatt Gooding, Slavica Tudzarova, Roberta J Worthington, et al.
Plos One|July 14, 2012
Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22John D Kelly, Tim J Dudderidge, Alex Wollenschlaeger, et al.
The Oncologist|August 23, 2024
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational studyFrancesco Schettini, Marianna Sirico, Marco Loddo, et al.
Frontiers in Oncology|July 15, 2021
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Silvia Paola Corona, Fabiola Giudici, et al.
Pageof 4